BEAUTY HEALTH CO/THE (SKIN)
US88331L1089 - Common Stock
Overall SKIN gets a fundamental rating of 2 out of 10. We evaluated SKIN against 36 industry peers in the Personal Care Products industry. The financial health of SKIN is average, but there are quite some concerns on its profitability. SKIN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SKIN had positive earnings in the past year.
SKIN had a positive operating cash flow in the past year.
SKIN had negative earnings in 4 of the past 5 years.
In the past 5 years SKIN reported 4 times negative operating cash flow.
1.2 Ratios
SKIN's Return On Assets of -11.76% is on the low side compared to the rest of the industry. SKIN is outperformed by 74.29% of its industry peers.
SKIN has a worse Return On Equity (-120.94%) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.76% | ||
| ROE | -120.94% | ||
| ROIC | N/A |
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 43.77%, SKIN is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
SKIN's Gross Margin has declined in the last couple of years.
SKIN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SKIN has less shares outstanding
The debt/assets ratio for SKIN is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.00, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
SKIN's Altman-Z score of 0.00 is on the low side compared to the rest of the industry. SKIN is outperformed by 82.86% of its industry peers.
A Debt/Equity ratio of 7.96 is on the high side and indicates that SKIN has dependencies on debt financing.
With a Debt to Equity ratio value of 7.96, SKIN is not doing good in the industry: 91.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.96 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0 |
ROIC/WACCN/A
WACC6.61%
2.3 Liquidity
A Current Ratio of 6.49 indicates that SKIN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.49, SKIN belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
SKIN has a Quick Ratio of 5.47. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.47, SKIN belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.49 | ||
| Quick Ratio | 5.47 |
3. Growth
3.1 Past
SKIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.87%.
SKIN shows a decrease in Revenue. In the last year, the revenue decreased by -6.27%.
Measured over the past years, SKIN shows a very strong growth in Revenue. The Revenue has been growing by 49.50% on average per year.
EPS 1Y (TTM)-90.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-99.41%
Revenue 1Y (TTM)-6.27%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Sales Q2Q%-22.89%
3.2 Future
SKIN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -31.54% yearly.
SKIN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.87% yearly.
EPS Next Y-225.38%
EPS Next 2Y-73.52%
EPS Next 3Y-31.54%
EPS Next 5YN/A
Revenue Next Year-14.69%
Revenue Next 2Y-3.92%
Revenue Next 3Y1.58%
Revenue Next 5Y6.87%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 85.00 indicates a quite expensive valuation of SKIN.
SKIN's Price/Earnings is on the same level as the industry average.
SKIN is valuated expensively when we compare the Price/Earnings ratio to 29.12, which is the current average of the S&P500 Index.
SKIN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 85 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SKIN's earnings are expected to decrease with -31.54% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.52%
EPS Next 3Y-31.54%
5. Dividend
5.1 Amount
No dividends for SKIN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEAUTY HEALTH CO/THE
NASDAQ:SKIN (11/12/2024, 8:00:02 PM)
Premarket: 1.61 -0.09 (-5.29%)1.7
-0.06 (-3.41%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap210.83M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 85 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.76% | ||
| ROE | -120.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.77% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.96 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.49 | ||
| Quick Ratio | 5.47 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-90.87%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-225.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.27%
Revenue growth 3Y49.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y